Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 9—September 2025

CME ACTIVITY - Research

Severe Group A Streptococcus Infection among Children, France, 2022–2024

Montserrat Sierra ColominaComments to Author , Alix Flamant, Guillaume Le Balle, Jérémie F. Cohen, Lionel Berthomieu, Stéphane Leteurtre, Yves Gillet, Etienne Javouhey, Stéphane Bechet, Corinne Levy, Robert Cohen, Agnès Ferroni, Damien Dubois, Miguel Angel Hernandez Martinez, Céline Plainvert, Asmaa Tazi, Camille Brehin, and ISAI Study Group,1
Author affiliation: CHU Toulouse, Toulouse, France (M. Sierra Colomina, G. Le Balle, L. Berthomieu, D. Dubois, C. Brehin); Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France (A. Flamant, J.F. Cohen, A. Ferroni); Lille University, CHU Lille, Lille, France (S. Leteurtre); Groupe Francophone de Réanimation et Urgences Pédiatriques, Lille (S. Leteurtre); CHU Lyon, Lyon, France (Y. Gillet, E. Javouhey); Association Clinique et Thérapeutique du Val de Marne, Créteil, France (S. Bechet, C. Levy); Groupe de Pathologie Infectieuse Pédiatrique, Créteil (R. Cohen); National Reference Centre for Streptococci, Assistance Publique-Hôpitaux de Paris, Paris Centre, Hôpital Cochin, Paris (M.A. Hernandez Martinez, C. Plainvert, A. Tazi)

Main Article

Table 4

Univariate and multivariate analysis of factors associated with PIMCU or PICU hospitalization in children with severe group A Streptococcus infections, France, 2022–2024*

Category PIMCU/PICU hospitalization No PIMCU/PICU hospitalization p value
Univariate analysis
Age group, y
<1 18/117 (15.4) 33/284 (11.6) 0.031
1 11/117 (9.4) 39/284 (13.7)
2 19/117 (16.2) 20/284 (7)
3–10 55/117 (47) 159/284 (56)
11–18 14/117 (12) 33/284 (11.6)
Immunosuppression 3/115 (2.6) 4/282 (1.4) 0.414
Comorbidities 16/116 (13.8) 36/283 (12.7) 0.773
Exposure to nonsteroidal antiinflammatory drug 13/112 (11.6) 21/272 (7.7) 0.223
Exposure to steroidal antiinflammatory drug 14/112 (12.5) 3/275 (1) <0.001
Viral infection in the 15 days before hospitalization 47/109 (28.9) 62/268 (23.1) <0.001
Type of infection
ENT 31/117 (26.5) 104/284 (36.6) <0.001
Pulmonary 44/117 (37.6) 40/284 (14.1)
Bone and joint 7/117 (6) 50/284 (17.6)
Cutaneous 16/117 (13.7) 47/284 (16.5)
Other 19/117 (16.2) 43/284 (15.1)
Multiple damage 50/117 (42.7) 96/284 (33.8) 0.091
Toxic rash
 17/117 (14.5)
 20/284 (7)
 0.019
Multivariate analysis, adjusted odds ratio (95% CI)
Viral infection in the 15 days before hospitalization 2.02 (1.21–3.37) 0.07
Osteoarticular damage 0.29 (0.11–0.77) 0.013
Pulmonary damage 2.11 (1.04–4.29)
 0.037

*Values are no. (%) except as indicated. Boldface indicates significance. ENT, ear-nose-throat; PICU, pediatric intensive care unit; PIMCU, pediatric intermediate care unit.

Main Article

1Additional members who contributed data are listed at the end of this article.

Page created: July 11, 2025
Page updated: August 21, 2025
Page reviewed: August 21, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external